# AIRCHILL Investor Snapshot

> One-page AIRCHILL investor snapshot: current development status, evidence boundary, financing milestone, closing conditions, key risks and diligence path.

- Canonical: https://www.medicalcooling.com/investor-snapshot/
- Markdown: https://www.medicalcooling.com/investor-snapshot/index.md
- Language: de-DE
- Last modified: 2026-08-14T22:41:25+00:00

AIRCHILL · Investor Snapshot · Last reviewed 15 August 2026

## What exists today. What is still unproven. What the next round must de-risk.

Development-stage · TRL ≈ 4 · no CE mark · no FDA clearance · not for patient use · no established clinical benefit

Medical Cooling / AIRCHILL public development status

AIRCHILL is being developed as a transport-ventilation platform with controlled respiratory cooling for time-critical care. This page is the short first-read layer before the full investor data room.

[Open Investor Data Room](https://www.medicalcooling.com/investor-data-room/)

[Review Evidence](https://www.medicalcooling.com/evidence/)

[Contact Medical Cooling](https://www.medicalcooling.com/contact/)

## The three questions first-time investors need answered

### 1. What exists today?

A physical laboratory demonstrator and a defined product concept; granted European and US patent rights; published and project-level mechanism/safety evidence; a public evidence, regulatory and market-access diligence layer.

### 2. What is not proven?

No AIRCHILL patient-efficacy dataset, no routine-use approval, no final design freeze, no completed QMS/certification package, no validated commercial adoption or reimbursement case, and no established clinical outcome benefit.

### 3. What does the next round finance?

The €7.5m planning round is designed around roughly 30 months of engineering, QMS/regulatory work, verification and validation, preclinical preparation and the path toward a planned first-in-patient feasibility gate in 2029.

## Current financing frame

- Current round: €7.5m planning case

- Planned runway: 30 months

- Indicative follow-on after Gate B: €10–15m

- First-in-patient feasibility: planned for 2029

- Base-case commercial revenue through 2031: €0

- Planning values are assumptions, not commitments, forecasts or guarantees

## What the public evidence supports

The public record supports continued investigation of the engineering and physiological mechanism and includes preclinical airway-safety work and limited human feasibility observations. Medical Cooling intentionally separates those findings from product-level clinical efficacy and patient-outcome claims.

[Evidence Overview](https://www.medicalcooling.com/evidence/)

[Research Register](https://www.medicalcooling.com/research-register/)

[Sources & Assumptions](https://www.medicalcooling.com/sources-assumptions/)

## The risks that should affect valuation and closing conditions

- Clinical benefit remains unproven; prior airway-cooling trials in the field are material risk context.

- The planned endotracheal product route must overcome the project’s own measured heat-transfer limitation associated with dead-space ventilation.

- EU Class IIb remains a planning assumption; US 510(k) versus De Novo remains to be tested through regulatory interaction.

- The granted patents are founder-controlled; assignment or an exclusive worldwide sublicensable licence to the operating company remains a defined financing step.

- Founder capacity, full-time leadership, QA/RA ownership and execution-team buildout require documentary de-risking.

- Customer discovery, signed LOIs, procurement validation and final pricing/unit economics are not represented as completed.

## Next value-inflection gate

The immediate investment case is not based on assumed revenue. It is based on converting a TRL ≈ 4 development programme into a verified, controlled and regulator-ready product package with explicit stop/go criteria. The strongest next milestone is a completed bench, airway-safety and verification package that materially reduces product and regulatory uncertainty.

## Diligence path

- Read the AIRCHILL product page for architecture, product scope and current status.

- Review the evidence page and research register for what is supported versus still hypothetical.

- Review regulatory and reimbursement assumptions separately from clinical claims.

- Use the Investor Data Room for the public document register, gaps and restricted-material map.

- Request transaction-sensitive documents only once investor fit is established.

[AIRCHILL Product](https://www.medicalcooling.com/airchill/)

[Regulatory & Reimbursement](https://www.medicalcooling.com/regulatory-reimbursement/)

[Investor Data Room](https://www.medicalcooling.com/investor-data-room/)

AIRCHILL is a development-stage medical technology project. This page is for research, planning and investor-diligence orientation. It is not medical advice, a representation of regulatory approval, an offer of securities, an investment recommendation or a guarantee of future performance.